As of 2025-07-22, the EV/EBITDA ratio of Can Fite Biopharma Ltd (CANF.TA) is -3.84. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CANF.TA's latest enterprise value is 46.96 mil USD. CANF.TA's TTM EBITDA according to its financial statements is -12.22 mil USD. Dividing these 2 quantities gives us the above CANF.TA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 12.6x | 7.9x |
| Forward P/E multiples | 8.7x - 12.9x | 10.5x |
| Fair Price | (2.34) - (3.45) | (2.49) |
| Upside | -295.0% - -387.5% | -307.7% |
| Date | EV/EBITDA |
| 2025-06-25 | -4.20 |
| 2025-06-24 | -4.55 |
| 2025-06-23 | -4.20 |
| 2025-06-22 | -4.20 |
| 2025-06-19 | -4.20 |
| 2025-06-18 | -4.20 |
| 2025-06-17 | -4.55 |
| 2025-06-16 | -4.55 |
| 2025-06-15 | -4.20 |
| 2025-06-12 | -4.20 |
| 2025-06-11 | -4.20 |
| 2025-06-10 | -4.20 |
| 2025-06-09 | -4.55 |
| 2025-06-08 | -4.55 |
| 2025-06-05 | -4.55 |
| 2025-06-04 | -4.55 |
| 2025-06-03 | -4.55 |
| 2025-05-29 | -4.20 |
| 2025-05-28 | -4.20 |
| 2025-05-27 | -4.55 |
| 2025-05-26 | -4.55 |
| 2025-05-25 | -4.20 |
| 2025-05-22 | -4.20 |
| 2025-05-21 | -4.20 |
| 2025-05-20 | -4.20 |
| 2025-05-19 | -4.55 |
| 2025-05-18 | -4.55 |
| 2025-05-15 | -4.20 |
| 2025-05-14 | -4.20 |
| 2025-05-13 | -4.55 |
| 2025-05-12 | -4.20 |
| 2025-05-11 | -4.20 |
| 2025-05-08 | -4.55 |
| 2025-05-07 | -4.90 |
| 2025-05-06 | -4.90 |
| 2025-05-05 | -4.90 |
| 2025-05-04 | -4.90 |
| 2025-04-29 | -4.55 |
| 2025-04-28 | -4.90 |
| 2025-04-27 | -5.26 |
| 2025-04-24 | -4.90 |
| 2025-04-23 | -4.90 |
| 2025-04-22 | -5.26 |
| 2025-04-21 | -5.26 |
| 2025-04-20 | -5.61 |
| 2025-04-17 | -5.26 |
| 2025-04-16 | -5.26 |
| 2025-04-15 | -5.96 |
| 2025-04-14 | -6.67 |
| 2025-04-10 | -5.96 |